Toronto, Ontario, June 04, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP) announced today the launch of a new LAB150 project aimed at developing a novel therapeutic agent for immuno-oncology. The research for the promising new approach comes from Dr. Jean Gariépy and his…
Tag: drug development
Funding for Sinai Health Netherton Syndrome project from partners Evotec and AmorChem
TORONTO, May 12, 2020 (GLOBE NEWSWIRE) — Toronto Innovation Acceleration Partners (TIAP), Evotec SE and AmorChem II Fund L.P. (AmorChem) are pleased to announce a $1.75M investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in…
Mental Health is the Focus of Our Fifth Project
Toronto, ON, June 11, 2019 (GLOBE NEWSWIRE) — It is estimated that 5% of the global population is affected by Major Depressive Disorder (MDD) at any given time. While there are many antidepressant drugs on the market, most of these drugs need weeks to take…
Two New Projects: Cystic Fibrosis and Respiratory Syncytial Virus
Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) — MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both…
First Project Announced!
Hamburg, Germany, and Toronto, Canada, Feb. 15, 2018 (GLOBE NEWSWIRE) — Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and MaRS Innovation announced today that they have identified the first project to be developed under their LAB150 partnership. After signing a collaboration agreement in…